WeightWatchers CEO Sima Sistani talks TikTok,...

Elon Musk’s SpaceX debuted on the Nasdaq in June with the largest IPO ever, raising a record $86 billion. But the stock has been on a wild ride ever since. Kara sits down with a panel of experts to assess SpaceX after its inaugural post-IPO earnings report and the first in a seri ...  Afficher plus

California is one of the most Democratic states in the nation. But former Fox News host and British American Steve Hilton is mounting a long-shot bid to be the state’s next Republican governor. He’s banking on voters’ disaffection with the state’s notoriously high cost of living ...  Afficher plus

Long before WeightWatchers became a weight loss empire, the legacy dieting company started as a small support group in the 1960s. The company rose to popularity preaching a message of moderation and making healthy choices. But in what some call a surprising pivot, WeightWatchers ...  Afficher plus

WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the ...

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Afficher plus

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Afficher plus